Cristina Ulecia-Morón

Cristina Ulecia-Morón

Auto-generated profile, based on publicly available information

Cristina Ulecia-Morón

Department of Pharmacology and Toxicology, Faculty of Medicine, University Complutense Madrid (UCM); Research Institute of Hospital 12 de Octubre (Imas12); University Institute of Research in Neurochemistry of the UCM (IUIN-UCM), Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
EAElísabet Alcocer-Gómez
Elísabet Alcocer-Gómez
CUCristina Ulecia-Morón
Cristina Ulecia-Morón
FMFabiola Marín-Aguilar
Fabiola Marín-Aguilar
TRTatyana Rybkina
Tatyana Rybkina
NCNieves Casas-Barquero
Nieves Casas-Barquero
Mario D. CorderoMario D. Cordero
Mario D. Cordero

1 August 2017 in Immunobiology
Verified
Journal Article
Closed access
PAPerla Abigail Alvarado-Vazquez
Perla Abigail Alvarado-Vazquez
LBLaura Bernal
Laura Bernal
CPCandler A. Paige
Candler A. Paige
RGRachel L. Grosick
Rachel L. Grosick
CVCarolina Moracho Vilrriales
Carolina Moracho Vilrriales
ERE. Alfonso Romero-Sandoval
E. Alfonso Romero-Sandoval

1 January 2020 in Immunobiology
Verified
Journal Article
Closed access
DFDavid Wilson Ferreira
David Wilson Ferreira
CUCristina Ulecia-Morón
Cristina Ulecia-Morón
PAPerla Abigail Alvarado-Vázquez
Perla Abigail Alvarado-Vázquez
KCKatharine Cunnane
Katharine Cunnane
CMCarolina Moracho-Vilriales
Carolina Moracho-Vilriales
ERE. Alfonso Romero-Sandoval
E. Alfonso Romero-Sandoval

1 February 2017 in Immunobiology
Verified
Journal Article
Closed access
LBLaura Bernal
Laura Bernal
AAAbigail Alvarado-Vázquez
Abigail Alvarado-Vázquez
DFDavid Wilson Ferreira
David Wilson Ferreira
CPCandler A. Paige
Candler A. Paige
CUCristina Ulecia-Morón
Cristina Ulecia-Morón
ERE. Alfonso Romero-Sandoval
E. Alfonso Romero-Sandoval

19 March 2021
Verified
Book Chapter
Closed access
David Martín-HernándezDavid Martín-Hernández
David Martín-Hernández
CUCristina Ulecia-Morón
Cristina Ulecia-Morón
ÁBÁlvaro G. Bris
Álvaro G. Bris
MPMarta P. Pereira
Marta P. Pereira
JCJavier Caso
Javier Caso

8 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
David Martín-HernándezDavid Martín-Hernández
David Martín-Hernández
IGIrene L. Gutiérrez
Irene L. Gutiérrez
MGMarta González-Prieto
Marta González-Prieto
KMKarina MacDowell
Karina MacDowell
JRJavier Robledo-Montaña
Javier Robledo-Montaña
LMLuis Menchén
Luis Menchén
The chronic inflammatory process that characterizes inflammatory bowel diseases (IBD) is mainly driven by T-cell response to microbial and environmental antigens. Psychological stress is a potential trigger of clinical flares of IBD, and sphingosine-1-phosphate (S1P) is involved in T-cell recruitment. Hence, stress impact and the absence of sphingosine kinase 2 (Sphk2), an enzyme of S1P metabolism, were evaluated in the colon of mice after sub-chronic stress exposure. Here, we show that sub-chronic stress increased S1P in the mouse colon, possibly due to a decrease in its degradation enzymes and Sphk2. S1P accumulation could lead to inflammation and immune dysregulation reflected by upregulation of toll-like receptor 4 (TLR4) pathway, inhibition of anti-inflammatory mechanisms, cytokine-expression profile towards a T-helper lymphocyte 17 (Th17) polarization, plasmacytosis, decrease in IgA+ lymphoid lineage cells (CD45+)/B cells/plasmablasts, and increase in IgM+ B cells. Stress also enhanced intestinal permeability. Sphk2 knockout mice presented a cytokine-expression profile towards a boosted Th17 response, lower expression of claudin 3,4,7,8, and structural abnormalities in the colon. Intestinal pathophysiology should consider stress and S1P as modulators of the immune response. S1P-based drugs, including Sphk2 potentiation, represent a promising approach to treat IBD.